HGH 191AA 10IU Dosage Protocol
Educational guide for reconstitution and daily dosing of 5-Amino-1MQ, a selective NNMT inhibitor studied for metabolic efficiency and fat metabolism support.
Quickstart Highlights
5-Amino-1MQ dosage protocols center on this selective, cell-permeable NNMT (Nicotinamide N-methyltransferase) inhibitor studied for its potential to support fat metabolism, preserve lean muscle mass, and elevate intracellular NAD+ levels. By blocking NNMT, 5-Amino-1MQ may help restore cellular energy balance and activate SIRT1 pathways associated with metabolic efficiency.
- Reconstitute: Add 3.0 mL bacteriostatic water → ~1.11 mg/mL concentration
- Typical daily range: 2.5–5 mg once or twice daily (subcutaneous)
- Easy measuring: At 1.11 mg/mL, 1 unit = 0.01 mL ≈ 11.1 mcg on a U-100 insulin syringe
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Subcutaneous Protocol (2 mL = 5 mg/mL)
| Phase | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 200 mcg once daily | 18 units (0.18 mL) |
| Week 2 | 300 mcg once daily | 27 units (0.27 mL) |
| Week 3 | 400 mcg once daily | 36 units (0.36 mL) |
| Week 4 | 500 mcg once daily | 45 units (0.45 mL) |
| Week 5 | 600 mcg once daily | 54 units (0.54 mL) |
| Week 6 | 700 mcg once daily | 63 units (0.63 mL) |
| Week 7 | 800 mcg once daily | 72 units (0.72 mL) |
| Week 8 | 900 mcg once daily | 81 units (0.81 mL) |
| Week 9 | 1000 mcg once daily | 90 units (0.90 mL) |
| Week 10 | 1100 mcg once daily | 99 units (0.99 mL) |
| Week 11+ | 1200 mcg once daily | 108 units (1.08 mL) |
Frequency: Inject once or twice daily subcutaneously. Due to the compound's plasma half-life of approximately 3.8–6.9 hours, twice-daily (BID) dosing may provide more sustained NNMT inhibition. Note: A single 10 mg vial provides only 2–4 days of research material at these doses.
Reconstitution Steps
- Remove the vial from freezer storage (−20 °C / −4 °F) and allow to equilibrate at room temperature for 15–20 minutes.
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved—solution should be clear (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 2–4 weeks.
How This Works
5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule that selectively inhibits Nicotinamide N-methyltransferase (NNMT). NNMT is an enzyme that methylates nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor. In states of obesity and metabolic dysfunction, NNMT is often overexpressed in adipose tissue, depleting nicotinamide and reducing NAD+ availability.
By inhibiting NNMT, 5-Amino-1MQ may spare nicotinamide for NAD+ synthesis, thereby activating SIRT1 (Sirtuin 1) pathways associated with mitochondrial biogenesis and fat oxidation. Preclinical studies indicate that NNMT knockdown or inhibition can protect against diet-induced weight gain and improve metabolic parameters without reducing food intake.
Potential Benefits & Side Effects
Observations from preclinical and early research literature.
- May support reductions in fat mass while preserving lean muscle in animal models
- Associated with elevated NAD+ levels and SIRT1 activation in preclinical studies
- Enhanced grip strength observed in aged mice when combined with exercise
- Generally well tolerated; occasional reports of mild headache, transient jitteriness, or injection-site reactions
- Long-term human safety data not established; this compound remains investigational
Injection Technique
General subcutaneous guidance from clinical best-practice resources.
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
- Slow injection may minimize any stinging sensation associated with the compound.
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes for each administration; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; a mild stinging sensation may occur due to the quinolinium structure.
- Document daily dose and site rotation to maintain consistency.
- The 10 mg vial format is suited for short-term tolerance assessment; extended protocols require multiple vials.
Important Disclaimer: This content is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. This is not medical advice and is for informational purposes only. Always consult with a qualified healthcare professional before starting any new research protocol.
References
Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity View Source
Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunctions View Source
NNMT: a novel therapeutic target for metabolic syndrome View Source